Citius Oncology, Inc.
CTORHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCitius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. The company carries a $91.0M market cap, placing it firmly in the micro-cap category. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
Market Cap
$91.0M
Beta
3.53
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.48
EPS (Fwd)
—
ROE
-126.6%
ROA
-29.1%
Cash
$16.6M
Total Debt
$10.2M
Free CF
-$31.2M
52W Change
-53.3%
Annual Financials
Cash vs Debt
Where CTOR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CTOR finished 3.70% below its 150-day moving average ($0.81) and 13.33% below its 200-day moving average ($0.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTOR overbought or oversold?
At the September 3, 2026 close, CTOR's RSI(14) was 45.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Citius Oncology, Inc. holds $16.6M in cash against $10.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$31.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -126.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Citius Oncology, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTOR.